Related Experiment Video
Updated: Jan 21, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia
Yinghui Zhu1, Xin He1, Yi-Chun Lin2
1Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Abstract:
Relapse remains the main cause of MLL-rearranged (MLL-r) acute lymphoblastic leukemia (ALL) treatment failure resulting from persistence of drug-resistant clones after conventional chemotherapy treatment or targeted therapy. Thus, defining mechanisms underlying MLL-r ALL maintenance is critical for developing effective therapy. PRMT1, which deposits an asymmetric dimethylarginine mark on histone/non-histone proteins, is reportedly overexpressed in various cancers. Here, we demonstrate elevated PRMT1 levels in MLL-r ALL cells and show that inhibition of PRMT1 significantly suppresses leukemic cell growth and survival. Mechanistically, we reveal that PRMT1 methylates Fms-like receptor tyrosine kinase 3 (FLT3) at arginine (R) residues 972 and 973 (R972/973), and its oncogenic function in MLL-r ALL cells is FLT3 methylation dependent. Both biochemistry and computational analysis demonstrate that R972/973 methylation could facilitate recruitment of adaptor proteins to FLT3 in a phospho-tyrosine (Y) residue 969 (Y969) dependent or independent manner. Cells expressing R972/973 methylation-deficient FLT3 exhibited more robust apoptosis and growth inhibition than did Y969 phosphorylation-deficient FLT3-transduced cells. We also show that the capacity of the type I PRMT inhibitor MS023 to inhibit leukemia cell viability parallels baseline FLT3 R972/973 methylation levels. Finally, combining FLT3 tyrosine kinase inhibitor PKC412 with MS023 treatment enhanced elimination of MLL-r ALL cells relative to PKC412 treatment alone in patient-derived mouse xenografts. These results indicate that abolishing FLT3 arginine methylation through PRMT1 inhibition represents a promising strategy to target MLL-r ALL cells.
Insights
Targeting PRMT1, an enzyme overexpressed in MLL-rearranged (MLL-r) acute lymphoblastic leukemia (ALL), inhibits leukemic cell growth. PRMT1 methylation of FLT3 is crucial for MLL-r ALL survival, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Relapse in MLL-rearranged (MLL-r) acute lymphoblastic leukemia (ALL) is driven by drug-resistant clones.
- Protein arginine methyltransferase 1 (PRMT1) is overexpressed in cancers and deposits asymmetric dimethylarginine marks.
Purpose of the Study:
- To investigate the role of PRMT1 in MLL-r ALL maintenance and therapeutic potential.
- To elucidate the mechanism of PRMT1 action in MLL-r ALL, focusing on Fms-like receptor tyrosine kinase 3 (FLT3).
Main Methods:
- Assessed PRMT1 levels in MLL-r ALL cells.
- Investigated the effect of PRMT1 inhibition on leukemic cell growth and survival.
- Utilized biochemical and computational analyses to study PRMT1-mediated FLT3 methylation at R972/973.
- Examined the impact of FLT3 methylation-deficient mutants on apoptosis and growth inhibition.
- Evaluated the combination therapy of a PRMT1 inhibitor (MS023) and a FLT3 inhibitor (PKC412) in patient-derived mouse xenografts.
Main Results:
- PRMT1 is elevated in MLL-r ALL cells, and its inhibition suppresses leukemic cell growth.
- PRMT1 methylates FLT3 at R972/973, which is critical for MLL-r ALL oncogenic function.
- FLT3 R972/973 methylation facilitates adaptor protein recruitment, impacting cell survival.
- Cells with methylation-deficient FLT3 showed increased apoptosis and growth inhibition compared to phosphorylation-deficient mutants.
- Combined treatment with MS023 and PKC412 enhanced MLL-r ALL cell elimination in vivo.
Conclusions:
- PRMT1 plays a critical role in MLL-r ALL pathogenesis by methylating FLT3.
- Targeting PRMT1-mediated FLT3 arginine methylation is a promising therapeutic strategy for MLL-r ALL.
- Combination therapy with PRMT1 and FLT3 inhibitors may overcome treatment resistance in MLL-r ALL.
Related Concept Videos
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Maintenance of the ES Cell State
Self-Evaluation Maintenance Model
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview

